Fox Run Management L.L.C. Makes New $86,000 Investment in ImmunityBio, Inc. (NASDAQ:IBRX)

Fox Run Management L.L.C. acquired a new stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) during the fourth quarter, according to its most recent filing with the SEC. The fund acquired 33,504 shares of the company’s stock, valued at approximately $86,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Swiss National Bank grew its holdings in ImmunityBio by 1.5% during the 4th quarter. Swiss National Bank now owns 274,000 shares of the company’s stock valued at $701,000 after buying an additional 4,000 shares in the last quarter. Teacher Retirement System of Texas boosted its position in shares of ImmunityBio by 20.4% in the fourth quarter. Teacher Retirement System of Texas now owns 41,742 shares of the company’s stock valued at $107,000 after acquiring an additional 7,067 shares during the period. Commonwealth Equity Services LLC grew its stake in ImmunityBio by 40.7% during the fourth quarter. Commonwealth Equity Services LLC now owns 28,955 shares of the company’s stock valued at $74,000 after acquiring an additional 8,380 shares in the last quarter. E Fund Management Co. Ltd. increased its holdings in ImmunityBio by 32.9% during the 4th quarter. E Fund Management Co. Ltd. now owns 38,900 shares of the company’s stock worth $100,000 after acquiring an additional 9,622 shares during the period. Finally, Copperwynd Financial LLC lifted its stake in ImmunityBio by 99.1% in the 4th quarter. Copperwynd Financial LLC now owns 20,087 shares of the company’s stock worth $51,000 after purchasing an additional 10,000 shares in the last quarter. 8.58% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on IBRX shares. D. Boral Capital restated a “buy” rating and set a $30.00 price target on shares of ImmunityBio in a research report on Thursday, March 13th. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of ImmunityBio in a research report on Thursday, March 13th. Finally, BTIG Research initiated coverage on ImmunityBio in a report on Friday, January 10th. They issued a “buy” rating and a $6.00 price target on the stock. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $12.19.

ImmunityBio Stock Performance

NASDAQ IBRX opened at $3.14 on Friday. ImmunityBio, Inc. has a 52-week low of $2.28 and a 52-week high of $10.53. The company has a fifty day moving average of $3.13 and a 200-day moving average of $3.60. The company has a market capitalization of $2.68 billion, a P/E ratio of -3.41 and a beta of 0.82.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.11. The firm had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $8.74 million. As a group, analysts forecast that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.